A
For investors
Understand the technical reality behind the investment case.
Assess maturity, remaining development, likely capital requirements, schedule exposure, and the execution conditions attached to a decision.
Explore diligence support
Biotechnology judgment for consequential decisions
Know what remains before you commit the capital.
AGL Bioadvisors helps investors and biotechnology management teams assess technical readiness, remaining work, cost, schedule, and execution risk—from focused diligence through commercial delivery.
Food technologyAgricultural technologyEnzymesFermentationIndustrial biotechnology
AGL Bioadvisors Ltd. working letterJuly 2026
A letter from Alan
We are flexible in the way that we work.
This evidence-safe excerpt is presented for private design review. Final wording and attribution require principal approval.
Two entry points
The question changes. The need for clear judgment does not.
B
For management teams
Add senior capacity at the point the program needs it.
Access complementary scientific, engineering, and management judgment for a defined question, a development program, or longer-term oversight.
See the engagement modelThe commercialization gap
Laboratory promise is not yet an execution plan.
The costly error is often not a weak idea. It is an inaccurate view of how far the technology has progressed—and what the remaining journey will demand.
When technical maturity is overstated, remaining work, capital, and time are understated. Runway tightens before the program reaches commercial operation. AGL’s role is to make that gap legible early enough to act.
01Readiness is overestimated
02Work and cost are understated
03Runway compresses
04Options narrow
How we help
Focused advice. Integrated execution judgment.
Each engagement begins with the decision in front of you. Scope can expand only when the work warrants it.
Pre-investment technical diligence
Test the technical story before capital is committed. We focus on what is proven, what remains uncertain, and what must happen next.
Readiness, cost, and schedule assessment
Translate laboratory progress into a practical view of remaining work, likely capital needs, delivery sequence, and execution risk.
Development-program steering
Bring senior scientific, engineering, and management judgment to critical decisions without building a full executive team too early.
Scale-up and delivery oversight
Connect development choices to plant, manufacturing, project, and delivery realities as a program moves toward commercial operation.
The Power Triangle
Three disciplines. One judgment.
Biotechnology decisions break down when science, implementation, and commercial priorities are assessed in isolation. AGL brings the three lenses into the same conversation.
- What: Is the biology ready?
- How: Can it be engineered and delivered?
- Where + when: Does the plan fit the capital and commercial path?
The principals
Complementary by design.
Each principal brings a distinct lens. The value sits in how those perspectives challenge and strengthen one another.
WhatBiological Vision
01Dr. Lori Giver, Ph.D.
The scientific lens: biological credibility, technical readiness, and the work required to move the science forward.
HowEngineering Precision
02Graham Aylen
The implementation lens: scale-up, plant, manufacturing, project constraints, and the path from process to operation.
Where + whenManagement Mastery
03Dr. Alan Shaw, Ph.D.
The commercial lens: capital, priorities, sequence, schedule, and the decisions that connect technology to value.
Portraits, titles, biographies, and alt text remain subject to each principal’s publication approval.
Flexible by design
Start with the decision. Scale with the work.
01Focused advice
A defined question, review, or diligence assignment.
02Program steering
Senior judgment across a development phase or inflection point.
03Delivery oversight
Longer-term support through scale-up, project, and manufacturing work.
Start a conversation
What decision is in front of you?
Share only enough context for an initial conversation. Do not include patient data, clinical data, proprietary research, or other sensitive biotechnology information.
01
Focused questions
02Senior response
03Right-sized scope